Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)

Delayed Quote. Delayed  - 07/27 04:59:32 pm
2.41 DKK   -1.23%
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by t..
07/05 BIOPORTO A/S : NGAL Exclusion patent is ruled invalid by the EPO &nd..
07/04 BIOPORTO A/S : decides to reapply for FDA approval of The NGAL TestT..
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/21/2016 07/22/2016 07/25/2016 07/26/2016 07/27/2016 Date
2.45(c) 2.45(c) 2.46(c) 2.44(c) 2.41 Last
227 387 93 041 59 974 232 060 181 039 Volume
+1.66% 0.00% +0.41% -0.81% -1.23% Change
More quotes
Company
BioPorto A/S is an in-vitro diagnostics company.It provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.The company focuses on the diagnosis of obesity, diabetes, primary immune deficiency, and kidney injury.Its products include The NGAL... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Latest news on BIOPORTO A/S
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by the EPO BioPo..
07/05 BIOPORTO A/S : NGAL Exclusion patent is ruled invalid by the EPO – to appe..
07/04 BIOPORTO A/S : decides to reapply for FDA approval of The NGAL TestTM
06/07 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
06/06 Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA'..
06/06 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
05/28 BIOPORTO A/S : The FDA rejects application for the registration og The NGAL Test..
05/19 BIOPORTO A/S : BioPortos NGAL Forms patent is upheld after EPO ruling
05/18 BIOPORTO A/S : NGAL Forms patent is upheld after EPO ruling
05/04 BIOPORTO A/S : Interim report, first quarter of 2016
More news
Sector news : Diagnostic & Testing Substances Manufacturers
10:22aDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- Update
08:55aDJBayer Reports Higher Second-Quarter Profit, Raises Guidance
08:37aDJBAYER : Second-Quarter Profit Rises 18.6%
08:35aDJBAYER : Second-Quarter Profit Rises 18.6%
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
More sector news : Diagnostic & Testing Substances Manufacturers
Advertisement
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Full-screen chart
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Managers
NameTitle
Peter Mørch Eriksen CEO & Investor Relations Contact
Thomas Magnussen Chairman
Michael Pålsson Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S-49.17%0
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results